| Q35222291 | A brief history of gene therapy |
| Q35873295 | A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo |
| Q34286445 | A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system |
| Q36680208 | Activation of H2AX and ATM in varicella-zoster virus (VZV)-infected cells is associated with expression of specific VZV genes |
| Q35995307 | Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice |
| Q40524547 | Advances in cancer gene therapy |
| Q40422915 | African green monkey kidney Vero cells require de novo protein synthesis for efficient herpes simplex virus 1-dependent apoptosis |
| Q35857229 | Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence. |
| Q40571051 | Amplicon-based herpes simplex virus vectors. |
| Q40137260 | An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells |
| Q45862004 | An efficient in vivo recombination cloning procedure for modifying and combining HSV-1 cosmids |
| Q39580097 | An enhanced packaging system for helper-dependent herpes simplex virus vectors |
| Q45754375 | Analysis of a multi-mutant herpes simplex virus type 1 for gene transfer into sympathetic preganglionic neurons and a comparison to adenovirus vectors |
| Q41526877 | Anti-oncogene Ribozymes for Cancer Gene Therapy |
| Q43934769 | Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir |
| Q36707752 | Apoptosis during herpes simplex virus infection |
| Q40551607 | Apoptosis in viral infections |
| Q74639680 | Cancer gene therapy |
| Q45741299 | Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. |
| Q45746815 | Delivery of herpes simplex virus amplicon-based vectors to the dentate gyrus does not alter hippocampal synaptic transmission in vivo |
| Q33873085 | Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption |
| Q39591444 | Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system |
| Q40908487 | Effects of herpes simplex virus on human oral cancer cells, and potential use of mutant viruses in therapy of oral cancer |
| Q62971299 | Engineering Herpes Simplex |
| Q40803029 | Enhanced reporter gene expression in the rat brain from helper virus-free HSV-1 vectors packaged in the presence of specific mutated HSV-1 proteins that affect the virion |
| Q44079762 | Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus |
| Q39550929 | Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects |
| Q45754922 | Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector |
| Q40606308 | Functional expression of ATM gene carried by HSV amplicon vector in vitro and in vivo |
| Q45773320 | Gene delivery into the brain using virus vectors |
| Q33917592 | Gene delivery with viral vectors for cerebrovascular diseases |
| Q34997896 | Gene therapy for the central nervous system in the lysosomal storage disorders |
| Q71653280 | Gene therapy for urologic cancer |
| Q24680275 | Gene therapy in clinical medicine |
| Q42113935 | General strategy for constructing large HSV-1 plasmid vectors that co-express multiple genes |
| Q33857478 | HIV protease as a target for retrovirus vector-mediated gene therapy |
| Q40922461 | HSV as a gene transfer vector for the nervous system |
| Q36288901 | HSV-1-based amplicon vectors: design and applications |
| Q33995752 | HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications |
| Q40769181 | Helper virus-free HSV-1 vectors packaged both in the presence of VSV G protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum |
| Q35870965 | Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. |
| Q40604183 | Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. |
| Q45747421 | Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo |
| Q58779571 | Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System |
| Q36444443 | Herpes simplex virus 1 (HSV-1) for cancer treatment |
| Q36898823 | Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism |
| Q39596594 | Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. |
| Q34070145 | Herpes simplex virus type 1-based amplicon vector systems |
| Q40395117 | Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia |
| Q45788035 | Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects |
| Q35863367 | Herpes simplex virus-based vectors |
| Q37160338 | High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection |
| Q40728386 | Human cytomegalovirus tegument protein pp71 directs long-term gene expression from quiescent herpes simplex virus genomes |
| Q41495440 | ICP0 gene expression is a herpes simplex virus type 1 apoptotic trigger |
| Q34545788 | ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells |
| Q37392882 | Immune responses to herpesviral vectors |
| Q35131218 | Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy |
| Q62971278 | Implications of maturation for viral gene delivery to skeletal muscle |
| Q40041827 | Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. |
| Q33468717 | Improved long-term expression from helper virus-free HSV-1 vectors packaged using combinations of mutated HSV-1 proteins that include the UL13 protein kinase and specific components of the VP16 transcriptional complex |
| Q48529105 | In vivo gene transfer into the adult mammalian central nervous system by continuous injection of plasmid DNA-cationic liposome complex |
| Q39579065 | Increased induction of apoptosis by a Sendai virus mutant is associated with attenuation of mouse pathogenicity |
| Q77802801 | Infection and spread of alphaherpesviruses in the nervous system |
| Q39876184 | Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific |
| Q44974102 | Introduction of the glutamate receptor subunit 1 into motor neurons in vitro and in vivo using a recombinant herpes simplex virus |
| Q42280576 | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain |
| Q43244057 | Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system |
| Q34387794 | Modulation of apoptosis during herpes simplex virus infection in human cells |
| Q40814855 | Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo |
| Q44943020 | Muscle maturation: implications for gene therapy |
| Q42805617 | Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase |
| Q33783411 | Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins |
| Q37363640 | Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon |
| Q43524051 | Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis |
| Q35868577 | Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. |
| Q41982319 | Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy. |
| Q45868232 | Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors |
| Q45889730 | Recent developments in gene therapy for oncology and hematology |
| Q34080884 | Recognition of virus infection and innate host responses to viral gene therapy vectors |
| Q39882313 | Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap |
| Q37248260 | Replication-defective herpes simplex virus vectors for gene transfer in vivo |
| Q40571058 | Replication-defective recombinant herpes simplex virus vectors. |
| Q36574880 | Replication-incompetent herpesvirus vector delivery of an interferon alpha gene inhibits human immunodeficiency virus replication in human monocytes |
| Q47832394 | Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector |
| Q42801965 | Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target |
| Q35886888 | The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27 |
| Q33643356 | The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells |
| Q35131100 | Toxicity and biodistribution of the serotype 2 recombinant adeno-associated viral vector, encoding Aquaporin-1, after retroductal delivery to a single mouse parotid gland |
| Q64377820 | Transfer of a foreign gene into the brain using adenovirus vectors |
| Q33824256 | Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0 |
| Q35903203 | Update on herpesvirus amplicon vectors |
| Q45754297 | Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells |
| Q39149034 | Viral Vector Biosafety in Laboratory Animal Research |
| Q45864370 | Viral oncoapoptosis of human tumor cells |
| Q41235446 | Viral vectors for modulating gene expression in neurons |
| Q33894621 | Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS |